SwanBio is now part of Spur Therapeutics.

Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.

This site will remain live until Q4 2024 as we transition content to our new site.

Patients & Families Resources

Our Pledge to Patients

At SwanBio, we believe forward progress for patients like you comes from a deep understanding. We strive to understand the challenges you face from inherited spinal cord-related disorders, we are dedicated to developing medicines that can make a difference in your life, and we are working with great urgency to make a meaningful impact.

We believe it is imperative to collaborate closely with you – and all patients – as well as advocacy organizations who represent you. We pledge to constantly listen and learn from your real-world experiences as we forge ahead to pioneer new medicines.

Patients are our inspiration and motivation to pave a path where there are few or no treatment options.

For any inquiries related to SwanBio’s clinical trials or studies, please email us at clinicaltrials@swanbiotx.com or call us at +1 (267) 417-6356. Click here to learn more about the CYGNET Study and here to learn more about the PROPEL clinical trial.

Resources for the AMN Community

Our experience includes strong relationships with patients and patient advocacy communities. If you or a loved one has questions about AMN or other spinal cord-related disorders, the following organizations can provide helpful information.